Can-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

A number of other brokerages have also weighed in on CANF. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st.

Can-Fite BioPharma Trading Up 2.0 %

Shares of CANF stock opened at $1.56 on Friday. The company has a market cap of $5.52 million, a PE ratio of -0.87 and a beta of 1.36. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The business’s fifty day simple moving average is $1.68 and its 200-day simple moving average is $2.24.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.